Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
March 10, 2022 16:01 ET
|
Codiak BioSciences, Inc.
– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for...
Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances
February 18, 2022 14:00 ET
|
Codiak BioSciences, Inc.
– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Codiak...
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
January 06, 2022 09:00 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential for a Broadly Protective Pan-Beta Coronavirus and Variant Vaccine
December 02, 2021 08:30 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
December 01, 2021 16:05 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing Expected 1H 2022
November 30, 2021 08:30 ET
|
Codiak BioSciences, Inc.
– Codiak’s first engineered exosome therapeutic candidate for systemic administration – – Single agent anti-tumor effect observed in preclinical models via macrophage reprogramming – – Phase 1...
Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts
November 16, 2021 06:45 ET
|
Codiak BioSciences, Inc.
– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no...
New Preclinical Data at SITC 2021 Show Broad Potential Utility of Codiak’s Engineered Exosomes
November 12, 2021 07:00 ET
|
Codiak BioSciences, Inc.
– exoSTING™ monotherapy suppressed tumor growth and improved overall survival in a preclinical model of leptomeningeal disease, an aggressive metastasis of cancer to the central nervous system – –...
Codiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational Progress
November 04, 2021 16:01 ET
|
Codiak BioSciences, Inc.
– Announced strategic long-term exosome manufacturing collaboration with Lonza – – Initial data readout from exoSTING™ clinical trial expected in Q4 2021; initial data from exoIL-12™ trial in...
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
November 02, 2021 08:00 ET
|
Codiak BioSciences, Inc.
Lonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipelineLonza and Codiak to establish a Center of Excellence focused on...